Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

IDE modifications reg

This article was originally published in The Gray Sheet

Executive Summary

Publication of a final version of the rule could be held up until after the Nov. 21 deadline stipulated by the FDA Modernization Act because the Office of Management and Budget has determined that the rule is "significant" and worthy of OMB's review, FDAers say. OMB has 90 days from June 17 to review the rule before it can be issued as a proposed rule in the Federal Register. The rule, which will spell out which modifications may be made to an investigational device exemption product or protocol without FDA notification, is one of eight rules and guidances that the agency's device center had planned for release by September ("The Gray Sheet" June 29, p. 7)
Advertisement
Advertisement
UsernamePublicRestriction

Register

MT010337

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel